Trials / Not Yet Recruiting
Not Yet RecruitingNCT06339216
A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer Previously Treated with Immunotherapy
Detailed description
To observe and evaluate the efficacy of Adebrelimab combined with Apatinib and Paclitaxel for Injection(Albumin Bound) in second-line treatment of advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound) | Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart. Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented. Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes. |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2024-12-30
- Completion
- 2026-11-30
- First posted
- 2024-04-01
- Last updated
- 2024-04-01
Source: ClinicalTrials.gov record NCT06339216. Inclusion in this directory is not an endorsement.